ASHLYNA Drug Patent Profile

« Back to Dashboard

Which patents cover Ashlyna, and when can generic versions of Ashlyna launch?

Ashlyna is a drug marketed by Glenmark Pharms Ltd and is included in one NDA.

The generic ingredient in ASHLYNA is ethinyl estradiol; levonorgestrel. There is one drug master file entry for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for ASHLYNA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for ASHLYNA
Drug Sales Revenues:	Drug sales revenues for ASHLYNA
DailyMed Link:	ASHLYNA at DailyMed

See drug prices for ASHLYNA

See drug sales revenues for ASHLYNA

US Patents and Regulatory Information for ASHLYNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glenmark Pharms Ltd	ASHLYNA	ethinyl estradiol; levonorgestrel	TABLET;ORAL	203163-001	Feb 23, 2015	AB	RX	No	No

Ashlyna Market Dynamics, Patent Position, FDA Status, and Financial Trajectory

Last updated: September 24, 2026

Ashlyna is an extended-cycle combined oral contraceptive containing levonorgestrel and ethinyl estradiol. Its commercial position is shaped by generic competition, low switching costs, limited brand differentiation, and the mature U.S. oral-contraceptive market. Public sources do not disclose Ashlyna-specific revenue, prescription volume, or profit figures. The product’s financial trajectory is therefore best assessed through market structure, regulatory status, pricing pressure, and manufacturer strategy rather than reported brand sales.

What is Ashlyna and how does it work?

Ashlyna is a 91-day oral contraceptive regimen. Each package contains:

Component	Strength	Role
Levonorgestrel	0.15 mg	Progestin
Ethinyl estradiol	0.03 mg	Estrogen
Ethinyl estradiol tablets	0.01 mg	Low-dose estrogen interval

The regimen is designed to reduce scheduled withdrawal bleeding to approximately four episodes per year. Like other combined hormonal contraceptives, Ashlyna prevents ovulation and produces additional contraceptive effects through changes in cervical mucus and the endometrium. The FDA label identifies the product for the prevention of pregnancy in females of reproductive potential.[1]

Ashlyna is an oral contraceptive, not a biologic. Biosimilar regulation is therefore not relevant. Competitive threats arise from generic oral contraceptives, branded extended-cycle products, intrauterine systems, implants, injectables, patches, rings, and over-the-counter contraceptive products.

What is the FDA regulatory status of Ashlyna?

Ashlyna is FDA-approved for contraception and is distributed in the United States as an oral tablet product. The product is associated with Glenmark Pharmaceuticals in U.S. labeling and commercial materials.[1][2]

The principal regulatory characteristics are:

Regulatory issue	Ashlyna position
Dosage form	Oral tablets
Therapeutic class	Combined hormonal contraceptive
Active ingredients	Levonorgestrel and ethinyl estradiol
Administration	Extended-cycle, 91-day regimen
FDA pathway	Generic-equivalent or abbreviated regulatory pathway relative to the reference product
Biosimilar exposure	None
Prescription status	Prescription contraceptive
Main reference product	Seasonique and related extended-cycle formulations
Primary regulatory risk	Manufacturing, labeling, supply, and postmarketing compliance

The market does not depend on new clinical efficacy data for every competing product. Generic entrants typically rely on bioequivalence and pharmaceutical equivalence requirements rather than duplicating the full clinical development program of the reference product.

What patents protect Ashlyna?

Ashlyna’s commercial protection is not based on a large, independently differentiated patent estate. Its active ingredients are longstanding contraceptive compounds, and the product’s principal commercial value comes from its formulation, dosing schedule, regulatory approval, manufacturing capability, and distribution access.

Potential intellectual-property categories include:

1. Composition patents covering levonorgestrel or ethinyl estradiol combinations.
2. Regimen patents covering extended-cycle administration.
3. Formulation patents covering tablet composition, packaging, or stability.
4. Manufacturing patents covering tablet production or quality-control methods.
5. Labeling protection associated with approved indications or prescribing information.

For a mature oral contraceptive, the most relevant exclusivity is usually regulatory and commercial rather than a durable composition-of-matter patent. FDA Orange Book records for the reference product should be reviewed to identify listed patents, patent-use codes, and expiration dates. Ashlyna itself is not generally treated as a high-value innovator product with a broad standalone Orange Book estate.[3]

Does Ashlyna have formulation patents?

No publicly established Ashlyna-specific formulation patent has the commercial profile of a major branded pharmaceutical patent estate. The product’s formulation may still be protected by manufacturing know-how, specifications, process controls, supplier qualifications, and confidential quality systems.

Those protections can delay or complicate a competitor’s launch without creating a long period of legal exclusivity. The most important barriers are often operational:

• Consistent low-dose hormone manufacturing.
• Stability across the 91-day package.
• Packaging that maintains tablet identity and sequencing.
• Compliance with FDA manufacturing standards.
• Supply of active pharmaceutical ingredients.
• Reliable distribution to retail, mail-order, and managed-care channels.

When does Ashlyna lose exclusivity?

Ashlyna is already a mature product in the U.S. market. Its competitive position is not based on an approaching single patent cliff comparable to a newly launched specialty drug. Generic competition and therapeutic substitution have existed throughout the product’s commercial life.

The relevant timeline is:

Period	Market event	Commercial effect
2000s	Extended-cycle oral contraceptives gain broader U.S. adoption	Established demand for quarterly bleeding regimens
2010s	Generic and branded alternatives expand	Increased payer and pharmacy substitution
2020s	Mature contraceptive market with multiple delivery systems	Continued price pressure and lower brand loyalty
Current market	Ashlyna competes on availability, formulary access, and price	Limited ability to sustain premium pricing

The absence of a major upcoming Ashlyna patent expiry means that value erosion is gradual rather than concentrated. Price pressure is driven by generic substitution, payer contracting, pharmacy benefit manager reimbursement, and product availability.

What is the Orange Book status of Ashlyna?

The FDA Orange Book primarily organizes approved drug products and patent information around reference-listed drugs and approved abbreviated applications. For Ashlyna, the practical Orange Book questions are:

• Whether Ashlyna is listed as an approved product.
• Which reference-listed drug supports the approval.
• Whether patents are listed against the reference product.
• Whether any patent-use codes apply to the contraceptive indication.
• Whether competing abbreviated applications have been approved.

The Orange Book does not establish commercial demand, market share, or product profitability. It also does not show all potentially relevant manufacturing know-how or non-patent barriers.[3]

For business planning, the Orange Book should be read together with FDA labeling, approval letters, ANDA records where available, and current wholesale and payer data.

Which companies compete with Ashlyna?

Ashlyna competes across two levels: directly against other extended-cycle oral contraceptives and indirectly against all reversible contraceptive methods.

Direct oral contraceptive competitors

Direct alternatives include:

• Seasonique.
• Amethia and other levonorgestrel/ethinyl estradiol extended-cycle products.
• Introvale.
• Quartette.
• Generic extended-cycle levonorgestrel/ethinyl estradiol products.
• Other combined oral contraceptives with monthly withdrawal bleeding.

The direct market is fragmented. Products may contain the same hormones but differ in tablet sequence, estrogen exposure, packaging, generic availability, and formulary placement.

Alternative contraceptive competitors

The broader market includes:

• Hormonal intrauterine systems.
• Copper intrauterine devices.
• Etonogestrel implants.
• Depot medroxyprogesterone injections.
• Transdermal patches.
• Vaginal rings.
• Progestin-only pills.
• Emergency contraceptives and nonprescription products.

Long-acting reversible contraceptives generally create greater switching costs and involve clinician procedures. Oral contraceptives have lower acquisition and switching barriers, which increases price sensitivity and substitution risk.

How strong is the Ashlyna patent estate?

Ashlyna has a weak-to-moderate IP position when measured against major branded pharmaceuticals. Its defensibility comes primarily from market execution rather than exclusivity.

Patent-estate factor	Assessment
Novel active ingredient	Weak
Composition-of-matter protection	Limited or expired for the underlying hormones
Extended-cycle regimen differentiation	Moderate historical value
Formulation protection	Potentially narrow
Manufacturing know-how	Relevant but difficult to quantify
Regulatory exclusivity	Mature or expired
Brand loyalty	Limited to moderate
Switching barriers	Low
Litigation leverage	Low relative to patented specialty products

The product can remain commercially viable despite limited patent strength if the manufacturer has favorable cost of goods, dependable supply, pharmacy access, and competitive contracting.

What generic entry risks exist for Ashlyna?

Generic entry risk is structurally high. The product is an oral tablet with well-established active ingredients, and prescribers and pharmacists are accustomed to substitution within the contraceptive category.

The main generic-entry scenarios are:

Scenario 1: Continued low-price competition

Multiple manufacturers remain in the market. Ashlyna retains a small but stable share through existing distribution and formulary placement. Net pricing declines gradually.

Scenario 2: Pharmacy-level substitution

Pharmacies dispense lower-cost equivalent products when permitted by state law, payer policy, and prescription instructions. Ashlyna’s brand volume falls even if the overall extended-cycle category grows.

Scenario 3: Supply-driven share gains

A competitor experiences manufacturing or supply problems. Ashlyna temporarily gains volume because contraceptive users and pharmacies prioritize product availability.

Scenario 4: Formulary exclusion

A payer excludes or disadvantages Ashlyna relative to a lower-cost equivalent. Volume declines rapidly because oral contraceptive prescribing is highly sensitive to copay and pharmacy coverage.

Are there Paragraph IV challenges involving Ashlyna?

A Paragraph IV certification is relevant when an ANDA applicant asserts that a patent listed for a reference drug is invalid, unenforceable, or will not be infringed. The existence and significance of any Paragraph IV challenge must be evaluated through FDA patent-listing records and federal court filings.

Ashlyna’s risk profile is different from that of a newly launched branded drug. The product is already exposed to generic competition, so a future Paragraph IV event would be more likely to affect a specific patent, formulation, or market segment than to create a new product-wide exclusivity cliff.

No high-value, widely reported Paragraph IV litigation campaign is associated with Ashlyna as a major commercial asset in the public record. The more relevant legal risks are ordinary ANDA competition, manufacturing disputes, labeling issues, and commercial contracting.

What patent litigation affects Ashlyna?

Ashlyna has not developed a litigation profile comparable to blockbuster branded drugs in oncology, immunology, or rare disease. Publicly visible litigation risk appears limited.

Relevant legal areas include:

• Patent disputes concerning extended-cycle contraceptive formulations.
• ANDA litigation involving reference products.
• Trademark disputes involving product names.
• Product-liability claims related to thromboembolic and cardiovascular risks.
• Manufacturing and supply-contract disputes.
• Regulatory enforcement involving labeling or current good manufacturing practices.

Product-liability exposure can be more financially significant than patent litigation for combined oral contraceptives. FDA labeling includes contraindications and warnings relating to smoking, thrombotic events, cardiovascular risk, hypertension, liver disease, and other conditions.[1]

What is the commercial market for Ashlyna?

Ashlyna operates in a large but mature U.S. contraceptive market. The principal commercial variables are:

Variable	Impact on Ashlyna
Prescription volume	Supports baseline demand but does not ensure brand retention
Generic substitution	Reduces branded unit share and pricing
Payer coverage	Determines patient out-of-pocket cost
Pharmacy inventory	Can produce short-term market-share shifts
Patient preference	Supports extended-cycle use for some patients
Clinician familiarity	Helps maintain prescribing continuity
Delivery-system competition	Limits long-term growth in oral products
OTC contraceptive expansion	May increase price pressure across the category

Ashlyna is unlikely to command the pricing power of a specialty therapy. Its value is tied to recurring prescription demand, manufacturing efficiency, and distribution scale.

What is the financial trajectory for Ashlyna?

Public company filings do not generally report Ashlyna revenue as a separate line item. Glenmark and other manufacturers report broader business segments, geographic sales, or portfolios rather than product-level sales for mature contraceptive brands.[2]

The likely financial trajectory is:

1. Early commercialization supported by extended-cycle contraceptive demand and brand recognition.
2. Revenue erosion as generic alternatives expand and payers negotiate lower net prices.
3. Margin compression from rebate activity, wholesaler discounts, and manufacturing competition.
4. Stabilization at a lower revenue base if the product retains formulary access.
5. Periodic volume increases when competing products face shortages or discontinuations.

Ashlyna’s financial profile is therefore likely to be a cash-generative mature product only if production costs remain low and channel access remains stable. It is unlikely to be a major growth driver without a new commercial strategy, a differentiated delivery system, a direct-to-consumer expansion, or a broader contraceptive portfolio.

How does Ashlyna compare with Seasonique and other extended-cycle contraceptives?

Factor	Ashlyna	Seasonique	Other generic extended-cycle products
Active ingredients	Levonorgestrel/ethinyl estradiol	Levonorgestrel/ethinyl estradiol	Often the same
Dosing concept	Extended cycle	Extended cycle	Extended cycle
Brand position	Mature, price-sensitive	Reference-brand heritage	Low-cost substitution
Patent leverage	Limited	Primarily tied to reference-product history and listed patents	Generally limited
Payer sensitivity	High	High, with possible brand preference	Very high
Primary advantage	Availability and price	Recognition and clinical familiarity	Lowest acquisition cost
Long-term growth	Limited	Limited in mature markets	Share capture rather than category expansion

Ashlyna’s most direct competitive advantage is usually economic rather than clinical. Where the active ingredients and dosing schedule are equivalent, payer and pharmacy economics often determine the dispensed product.

What licensing deals affect Ashlyna?

No major publicly disclosed licensing transaction has made Ashlyna a material standalone asset. Mature oral contraceptive products are often commercialized through internal portfolios, supply arrangements, contract manufacturing, or regional distribution agreements rather than headline licensing deals.

Any commercial agreement would likely concern:

• U.S. distribution.
• Product supply.
• Authorized generic rights.
• Regional commercialization.
• Manufacturing transfer.
• Portfolio acquisition.

The absence of a public licensing transaction limits the ability to assign a separate transaction value to Ashlyna.

What manufacturing and geographic barriers affect Ashlyna?

Ashlyna’s geographic market is primarily the United States, where FDA approval, pharmacy benefit management, and state substitution rules determine commercial access. International markets require separate regulatory approvals and may use different brand names, packaging, or contraceptive labeling.

Manufacturing barriers are moderate. The active ingredients are established, but low-dose hormonal products require tight control of:

• Content uniformity.
• Dissolution.
• Stability.
• Tablet sequencing.
• Packaging.
• Batch release testing.
• Contamination and cross-contact controls.

A manufacturing interruption can have an immediate commercial effect because contraceptive patients and pharmacies often switch quickly when a product is unavailable.

Key Takeaways

• Ashlyna is an extended-cycle levonorgestrel and ethinyl estradiol oral contraceptive.
• Its market is mature, competitive, and highly sensitive to generic substitution and payer coverage.
• The product does not have the patent profile of a newly launched branded drug.
• Public sources do not disclose Ashlyna-specific revenue or profitability.
• Financial performance depends on manufacturing cost, formulary access, supply reliability, and pharmacy distribution.
• Biosimilar risk is irrelevant because Ashlyna is a small-molecule oral contraceptive.
• Paragraph IV and patent-litigation exposure appear limited compared with major branded pharmaceutical products.
• The most probable long-term trajectory is stable or declining revenue with periodic share gains during competitor shortages.

FAQs About Ashlyna Market and Patent Risk

Is Ashlyna still available in the United States?

Ashlyna has been marketed as a prescription extended-cycle oral contraceptive, but current availability can vary by wholesaler, pharmacy, manufacturer, and product status. FDA labeling and commercial pharmacy databases provide the most relevant product-level availability information.[1]

Is Ashlyna the same as Seasonique?

Ashlyna and Seasonique use the same general extended-cycle contraceptive concept and contain levonorgestrel and ethinyl estradiol, with low-dose estrogen tablets in the final interval. In practice, substitution depends on FDA equivalence, prescription instructions, payer coverage, and pharmacy policy.

Can pharmacies automatically substitute a generic for Ashlyna?

Substitution depends on the product’s FDA equivalence designation, state pharmacy law, payer rules, and prescriber instructions. Pharmacists may need to follow state-specific requirements for notifying the prescriber or patient.

Does Ashlyna have a biosimilar competitor?

No. Biosimilars apply to biological products. Ashlyna is a small-molecule oral tablet and competes with generic equivalents and other contraceptive delivery systems.

What is the biggest commercial risk to Ashlyna?

The largest risk is sustained price and volume erosion from generic extended-cycle products and alternative contraceptive methods. Manufacturing interruptions and unfavorable formulary decisions can accelerate the decline.

References

1. U.S. Food and Drug Administration. (n.d.). Ashlyna: Levonorgestrel and ethinyl estradiol tablets, and ethinyl estradiol tablets prescribing information.
2. Glenmark Pharmaceuticals Ltd. (2024). Annual report 2023-2024.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.